Biotransformation of [14C]-ixazomib in patients with advanced solid tumors: characterization of metabolite profiles in plasma, urine, and feces
This metabolite profiling and identification analysis (part of a phase I absorption, distribution, metabolism, and excretion study) aimed to define biotransformation pathways and evaluate associated inter-individual variability in four patients with advanced solid tumors who received [14C]-ixazomib.
After administration of a single 4.1-mg oral dose of [14C]-ixazomib (total radioactivity [TRA] ~ 500 nCi), plasma (at selected timepoints), urine, and fecal samples were collected before dosing and continuously over 0–168-h postdose, followed by intermittent collections on days 14, 21, 28, and 35. TRA analysis and metabolite profiling were performed using accelerator mass spectrometry. Radiolabeled metabolites were identified using liquid chromatography/tandem mass spectrometry.
Metabolite profiles were similar in plasma, urine, and feces samples across the four patients analyzed. All metabolites identified were de-boronated. In AUC0–816 h time-proportional pooled plasma, ixazomib (54.2% of plasma TRA) and metabolites M1 (18.9%), M3 (10.6%), and M2 (7.91%), were the primary components identified. M1 was the major metabolite, contributing to 31.1% of the 76.2% of the total dose excreted in urine and feces over 0–35-day postdose. As none of the identified metabolites had a boronic acid moiety, they are unlikely to be pharmacologically active.
Hydrolytic metabolism in conjunction with oxidative deboronation appears to be the principal process in the in vivo biotransformation pathways of ixazomib. The inference of formation-rate-limited clearance of ixazomib metabolites and the inferred lack of pharmacologic activity of identified circulating metabolites provides justification for use of parent drug concentrations/systemic exposure in clinical pharmacology analyses.
KeywordsIxazomib Biotransformation Boronic acid Accelerator mass spectrometry Phase I
The authors thank all patients and their families, as well as all physicians, nurses, study coordinators, and study center staff for participating in the studies that contributed data for this analysis. The authors also acknowledge Fiona Scott and Laura Webb, of FireKite, an Ashfield company, part of UDG Healthcare plc, who provided medical writing assistance, which was funded by Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; and Renda Ferrari, PhD, of Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, for editorial support.
This study was funded by Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Compliance with ethical standards
Conflict of interest
SP, MP, NG, MH, KV, J-TW, CX, XZ, and SC are employees of Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Informed consent was obtained from all individual participants included in the study. This study complied with Good Publication Practice 3 ethical guidelines (Battisti WP et al. Ann Intern Med. 2015;163:461–464), the Declaration of Helsinki, and the International Conference on Harmonization Guideline for Good Clinical Practice.
- 4.Merlini G, Sanchorawala V, Zonder JA et al (2014) Long-term outcome of a phase 1 study of the investigational oral proteasome inhibitor (PI) ixazomib at the recommended phase 3 dose (RP3D) in patients (pts) with relapsed or refractory systemic light-chain (AL) amyloidosis (RRAL). Blood 124(21):3450–3450Google Scholar
- 7.Gupta N, Hanley M, Venkatakrishnan K et al (2018) Effects of strong CYP3A inhibition and induction on the pharmacokinetics of ixazomib, an oral proteasome inhibitor: results of drug–drug interaction studies in patients with advanced solid tumors or lymphoma and a physiologically based pharmacokinetic analysis. J Clin Pharmacol 58(2):180–192CrossRefGoogle Scholar
- 12.United States Food & Drug Administration (2015) NINLARO (ixazomib) capsules, for oral use. United States prescribing information, November 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208462lbl.pdf
- 19.United States Food & Drug Administration (2018) Guidances (drugs). https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
- 20.European Medicines Agency (2008) ICH topic S9 nonclinical evaluation for anticancer pharmaceuticals. https://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002867.pdf